GlassScriptPhysician profile
Nichole C Hendry
NPI 1225173891
$7,133.86
in general payments reported to CMS, 2019-2025
56 companies · $2,971 in 2025
The $2,971 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,224 · 2023: $1,081 · 2024: $1,858 · 2025: $2,971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,889 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,888.65 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $870.56 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $567.49 | 2023-2025 | Enhertu, Calquence, Tagrisso |
| Janssen Biotech, INC. | $435.65 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Pfizer INC. | $403.29 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $351.94 | 2022-2025 | Keytruda, Welireg, Reblozyl |
| Abbvie INC. | $340.98 | 2022-2025 | |
| Daiichi Sankyo INC. | $222.76 | 2022-2025 | Injectafer, Enhertu, Datroway |
| Astellas Pharma US INC | $213.98 | 2022-2025 | Xtandi, Xospata, Padcev |
| Lilly USA, LLC | $205.62 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $204.54 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $202.22 | 2022-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $187.31 | 2022-2025 | Venclexta, Polivy, Tecentriq |
| Takeda Pharmaceuticals U.S.A., INC. | $172.78 | 2022-2025 | Iclusig, Alunbrig, Ninlaro |
| Sobi, INC | $165.65 | 2024-2025 | |
| Incyte Corporation | $152.36 | 2022-2025 | Monjuvi, Jakafi, Zynyz |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $137.81 | 2022-2025 | Fotivda |
| Glaxosmithkline, LLC. | $135.99 | 2022-2025 | Ojjaara, Blenrep |
| Madrigal Pharmaceuticals | $131.02 | 2025 | Rezdiffra |
| Array Biopharma INC | $116.12 | 2023-2025 | Mektovi, Braftovi, Tukysa |
| Taiho Oncology, INC. | $113.32 | 2022-2025 | |
| Genzyme Corporation | $105.34 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.09 | 2024-2025 | Gilotrif |
| Jazz Pharmaceuticals INC. | $97.60 | 2022-2025 | |
| Emd Serono, INC. | $97.24 | 2022-2025 | |
| Eisai INC. | $91.04 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $89.32 | 2022-2025 | Xpovio |
| Adc Therapeutics America, INC. | $75.72 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $69.17 | 2022-2024 | Libtayo |
| Stemline Therapeutics INC. | $66.64 | 2025 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $64.86 | 2022-2024 | |
| Mirati Therapeutics, INC. | $63.60 | 2023-2024 | Krazati |
| G1 Therapeutics, INC. | $62.98 | 2022 | |
| Seagen INC. | $62.83 | 2022-2023 | Tukysa |
| Spectrum Pharmaceuticals INC. | $62.60 | 2024-2025 | Rolvedon |
| Genmab U.S., INC. | $61.53 | 2022-2025 | Epkinly |
| Beone Medicines USA, INC. | $57.93 | 2025 | Tevimbra, Brukinsa |
| Exelixis INC. | $57.85 | 2024-2025 | Cabometyx |
| Puma Biotechnology, INC. | $54.15 | 2024-2025 | |
| Immunocore Limited | $49.74 | 2025 | Kimmtrak |
| Servier Pharmaceuticals LLC | $46.81 | 2022-2025 | |
| Deciphera Pharmaceuticals INC. | $40.99 | 2022-2024 | Qinlock |
| Rigel Pharmaceuticals, INC. | $40.19 | 2023-2024 | Rezlidhia, Tavalisse |
| Pharmaessentia USA Corporation | $29.07 | 2024 | Besremi |
| Gilead Sciences, INC. | $28.90 | 2025 | Trodelvy |
| Cti Biopharma Corp. | $27.34 | 2022-2023 | Vonjo |
| Sumitomo Pharma America, INC. | $22.91 | 2025 | Orgovyx |
| Novocure INC. | $22.74 | 2025 | Optune Lua (Novottf-200t) |
| Springworks Therapeutics, INC. | $19.91 | 2025 | Ogsiveo |
| Verastem, INC. | $19.77 | 2025 | Avmapki Fakzynja Co-Pack |
| Beigene USA, INC. | $17.82 | 2024 | Brukinsa |
| Epizyme, INC. | $17.28 | 2022 | |
| Morphosys, US INC. | $16.52 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.21 | 2024 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $14.79 | 2023 | Monoferric |
| Coherus Oncology, INC. | $14.31 | 2025 | Loqtorzi |
| Helsinn Therapeutics (U.S.), INC. | $13.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nichole Hendry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.